Deal facts
- Buyer
- AEGROS BIDCO LIMITED
- Target
- ALLIANCE PHARMA PLC
- Deal value
- Not disclosed
- Announced
- 12 May 2025
- Status
- Completed
- Sector
- Healthcare
- Country
- United Kingdom
- Consideration
- cash
Sources
AEGROS BIDCO LIMITED has agreed to acquire Alliance Pharma PLC in a strategic acquisition within the pharmaceutical sector. The transaction was announced on 12 May 2025 and completed two days later on 14 May 2025. Consideration for the deal was provided entirely in cash, although the specific financial value of the transaction was not disclosed to the public. The target company operates from the United Kingdom, and the deal represents a significant consolidation within the industry.
The acquisition marks the conclusion of the negotiation phase, with the transaction now fully completed. Regulatory approvals were secured to facilitate the transfer of ownership from the public company to the new private owner. This strategic move allows the buyer to integrate the target's assets and operations into its existing portfolio. The deal structure ensures a clean transition of control without the need for further regulatory intervention. The transaction is now final and effective.
More M&A Tools
Explore the Toolkit
Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.
Access nowDeal timeline
1 update- Court sanction
AEGROS BIDCO LIMITED to acquire ALLIANCE PHARMA PLC
{ "headline": "COURT SANCTION OF THE SCHEME OF ARRANGEMENT", "issuer": "Alliance Pharma (APH)", "announcement_date": "2025-05-12T14:49:00", "category_code": "Scheme of Arrangement", "body": "FOR IMMEDIATE RELEASE \n\n 12 May 2025 \n\n RECOMMENDED ACQUISITION \n\n OF \n\n ALLIANCE PHARMA PLC \n\n BY \n\n AEGROS BIDCO LIMITED \n\n (a newly incorporated company to be indirectly owned by DBA
LSE RNS
Explore
Browse adjacent archives
Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.
Similar deals
Similar deals
Other Healthcare M&A activity tracked by Exit Mode.
Circle Health Holdings Limited to acquire CHC Healthcare Holdings Limited
Circle Health Holdings Limited has agreed to acquire CHC Healthcare Holdings Limited in a strategic acquisition within the healthcare sector. Both entities are based in…
- Buyer
- Circle Health Holdings Limited
- Target
- CHC Healthcare Holdings Limited
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
Cronos Group Inc. to acquire CanAdelaar B.V.
Cronos Group Inc. has agreed to acquire CanAdelaar B.V. in a strategic acquisition within the healthcare sector. The Canadian buyer will purchase the Dutch target for a…
- Buyer
- Cronos Group Inc.
- Target
- CanAdelaar B.V.
- Deal value
- EUR 57,500,000
- Deal type
- strategic acquisition
Alaunos Therapeutics, Inc. to acquire Velaris Therapeutics, Inc.
Alaunos Therapeutics, Inc. has agreed to acquire Velaris Therapeutics, Inc. in a strategic acquisition. The transaction was announced on 13 October 2026 and was complete…
- Buyer
- Alaunos Therapeutics, Inc.
- Target
- Velaris Therapeutics, Inc.
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
STERIS Corporation to acquire Xodus Medical, Inc.
STERIS Corporation has agreed to acquire Xodus Medical, Inc. in a strategic transaction valued at two billion US dollars. The healthcare deal was announced on 11 October…
- Buyer
- STERIS Corporation
- Target
- Xodus Medical, Inc.
- Deal value
- USD 2,100,000,000
- Deal type
- strategic acquisition
Hepion Pharmaceuticals, Inc. to acquire Gravitas Life Sciences, LLC
Hepion Pharmaceuticals, Inc. has agreed to acquire Gravitas Life Sciences, LLC in a strategic acquisition. The transaction, valued at 4.25 million US dollars, was comple…
- Buyer
- Hepion Pharmaceuticals, Inc.
- Target
- Gravitas Life Sciences, LLC
- Deal value
- USD 4,250,000
- Deal type
- strategic acquisition
Buyer history
AEGROS BIDCO LIMITED
See every published Exit Mode archive entry where this buyer appears.
View buyer profileMethodology
How this page is built
Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.
Back to the archive
